MedTrace Logo

A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)

NCT02772575 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-01-31

No results posted yet for this study

Summary

The purpose of this study is to see if certain genes the tumor can help predict how the tumor will respond to Trans-Arterial Embolization (TAE). A gene is the basic physical and functional unit of heredity. Genes are made up of DNA; DNA (deoxyribonucleic acid) is the hereditary material in humans. Identifying a gene that can predict how liver tumors will respond to TAE will also help to determine if adjuvant therapy will be needed after TAE.

Conditions

Interventions

PROCEDURE

Hepatic trans-arterial embolization (TAE)

DEVICE

MRI/CT scan

PROCEDURE

biopsy

OTHER

blood draw

Sponsors & Collaborators

Principal Investigators

  • Etay Ziv, MD, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772575 on ClinicalTrials.gov